Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer

NCT04095689 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Stopping rules met per protocol, trial will be terminated

Conditions

Triple Negative Breast Cancer
Anthracycline-refractory TNBC

Interventions

DRUG: Docetaxel
DRUG: Pembrolizumab
DRUG: IL-12 gene therapy

Sponsor

The Methodist Hospital Research Institute

Collaborators

Merck Sharp & Dohme LLC